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Enzymatic activities of Carboxylesterase (CE) Glutathione S-Transferase (GST) and Carbonyl Reductase (CBR) 
measured in F. hepatica recovered from sheep treated with triclabendazole (10 mg/Kg.).  
*Graphical abstract (for review)
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I˂n vivo assessment of CE, GST and CBR in F. hepatica recovered to TCBZ treated sheep  ˂
 ˂Increase of the metabolite sulfoxide (TCBZSO) and sulfone (TCBZSO2)  ˂
I˂ncrease in enzymatic activity at 24 and 48 h PT of the three enzymes tested.  ˂
T˂he highest enzymatic activity was observed after peak of TCBZSO (active metabolite)  ˂ 
R˂eturn of enzyme activities to basal values to 60h PT  ˂
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ABSTRACT  19 
Fasciolasis is a zoonotic parasitic disease caused by Fasciola hepatica and its control is mainly 20 
based on the use of triclabendazole (TCBZ). Parasite resistance to different anthelmintics is 21 
growing worldwide, including the resistance of F. hepatica to TCBZ. In the present work we 22 
evaluate “in vivo” the activity of xenobiotic metabolizing enzymes of phase I (Carboxyl esterases) 23 
and phase II (Glutathione S-transferases and Carbonyl reductases) recovered of flukes from sheep 24 
treated with TCBZ . All three enzymes showed increased activity in TCBZ flukes returning 60 25 
hours post-treatment at similar to baseline unexposed flukes. TCBZ action may induce secondary 26 
oxidative stress, which may explain the observed increment in activities of the analyzed enzymes as 27 
a defensive mechanism. The enzymes analyzed are candidates to participate actively in the 28 
development of resistance at TCBZ in F. hepatica.  29 
 30 
 KEYWORDS 31 
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Fasciolasis is a zoonotic parasitic disease caused by the trematode Fasciola hepatica. Its control is 34 
mainly based on the use of triclabendazole (TCBZ), a halogenated benzimidazole thiol derivative 35 
which shows excellent efficacy against both juvenile (immature) and adult stages. In the case of 36 
anthelmintics, the induction of anthelmintics metabolizing enzymes could increase anthelmintics 37 
deactivation in parasites bodies and by this way facilitate the surviving of some helminthes 38 
individuals exposed to anthelmintic therapy [1]. This process can start anthelmintic resistance 39 
phenomenon. Parasite resistance to different anthelmintics is growing worldwide, including the 40 
resistance of F. hepatica to TCBZ.  The xenobiotic metabolizing enzymes (XME) of parasitic 41 
helminthes may protect these organisms against toxic effects of anthelmintics, and the ability to 42 
inactivate anthelmintics via biotransformation processes can represent an advantageous defense 43 
strategy of the parasites [2].  44 
The carboxylesterases (CEs) are members of XME and are α, β- serine hydrolase multigene family 45 
that hydrolyzes esterified xenobiotics to alcohol and carboxylic acid products.  In the liver fluke 46 
eight esterases were distinguishable [3]. Others XME, the Glutathione S-transferase (GST) appear 47 
to be the major phase II detoxification system present in parasitic worms. In the liver fluke, GST 48 
account for as much as 4% of the total soluble protein, with a widespread distribution in the 49 
parasites tissues suggesting important physiological roles. [4]. The XME Carbonyl reductase (CBR) 50 
constitutes the family of the aldo-keto reductases in human and other mammalian tissues [5] is a 51 
cytosolic monomeric, NADPH-depend nt oxidoreductase reducing a wide variety of endogenous 52 
and xenobiotic carbonyl compounds, which exert toxic effects on biological systems [6]. The most 53 
of studies concerning the metabolic response of liver fluke against the anthelminthic TCBZ only 54 
have referred to “in vitro” or “ex vivo” test models. The increased activity of Flavin monooxigenase  55 
(XME phase I) [7] and GST (XME phase II) [8] in the flukes TCBZ resistant (Sligo strain) provides 56 
an understanding of the phenomenon of resistance. This overexpression confirms that manifestation 57 
is a multienzymatic response involving more than one metabolic pathway [8]. In F. hepatica at 58 
present is unknown if CE and CBR are inducible enzymes from the action of TCBZ, if such action 59 
is confirmed, this enzymes would be likely candidates to participate actively in the phenomenon of 60 
resistance to this drugs. In this work, we evaluate, “in vivo”, the action of XME of phase I (CEs) 61 
and phase II (GST and CBRs) of F. hepatica recovered from TCBZ treated sheep. 62 
Ten parasite-free Corriedale weaned lambs were orally inoculated with 200 metacercariae of F. 63 
hepatica TCBZ-susceptible (Cullompton strain). This metacercariae were kindly provided by 64 
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Professor I. Fairweather, School of Biology and Biochemistry, The Queens University of Belfast, 65 
Northern Ireland, UK. For details of the history of this fluke strain, see [9]. The infection was 66 
confirmed 16 weeks later by the presence of eggs in faeces and indirect estimation of liver damage 67 
after determination of high levels of Glutamate Dehydrogenase and Gamma Glutamyl Transferase 68 
activities. The animals were treated orally with TCBZ Novartis
®
 (10 mg/kg) and stunned and 69 
exsanguinated immediately at 0, 3, 24, 48 and 60 h post-treatment (PT). Animal procedures and 70 
management protocols were approved by the Ethics Committee according to Animal Welfare Policy 71 
(act 087/02) of the Faculty of Veterinary Medicine, UNCPBA, Argentina 72 
http://www.vet.unicen.edu.ar , and to internationally accepted animal welfare guidelines [10] 73 
The parasites were rinsed extensively with NaCl 0.9%, at 37 ºC to remove bile and/or adhering 74 
materials according to method previously described [11]. Flukes were transported to the laboratory 75 
in flasks filled with phosphate buffer (PB) (0.1 M, pH 7.4) at 4 ◦C. All subsequent operations were 76 
performed between 0 and 4 ◦C. Each parasite was cut into small pieces and washed several times 77 
with PB. Samples were homogenized (1:1) in PB, pH 7.4, centrifuged at 10,000×g for 20 min and 78 
the resulting supernatant centrifuged at 100,000×g for 60 min [12]. The supernatant obtained 79 
(cytosolic fraction) was collected and stored at −80 ºC until assay. The pellets, (microsomal 80 
fraction), was suspended in 0.1 M PB, collected and stored at −80 ◦C until assay. Protein content 81 
was determined using the Lowry method with bovine serum albumin as standard [13].  82 
GST enzymatic activity in cytosolic fractions was monitored by a continuous spectrophotometric 83 
method [14] using 1-chloro- 2,4 -dinitrobenzene  as substrate, the  analyzed protein samples varied 84 
from 0.005 to 0.05 mg.  CE enzymatic activity in microsomal fractions of F. hepatica was 85 
determined using 0.33 mM p-nitrophenyl acetate as substrate in phosphate buffer saline (PBS) pH. 86 
7.2 according to a previously described method [15], the analyzed protein samples varied from 87 
0.003 to 0.010 mg. The amount of p-nitro phenol released by the enzymatic reaction was measured 88 
spectrophotometrically at 405 nm. Absorbance values were converted to µmol of hydrolyzed 89 
substrate/minute/mg. protein. The CBR activity, was measured using menadione  as substrate 90 
according to a previously published procedure [16], the analyzed protein samples varied from 91 
0.0025 - 0.005 mg. Ten repetitions (n = 10) for each time and enzymatic activity were done. 92 
The samples were analyzed by HPLC to determine the concentration of TCBZ and its 93 
metabolites following the methodology previously described [17]. Data were compared 94 
statistically by two-way ANOVA using the Bonferroni test as the post-ANOVA analysis with 95 
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Graph Pad Instant® 3.0 software. The three enzymes tested (CE, GST and CBR) exhibited an 96 
increase activity in the TCBZ treated flukes. These increases within the flukes was followed 97 
behind the peak of TCBZSO concentration (Table 1B). The highest activities for CE were 98 
observed at 48 h. PT (5170 nmol/ min. / mg. protein) compared to that measured in the cytosolic 99 
fraction obtained from control flukes (1450 nmol/min/mg.protein) which were not exposed to the 100 
drug. The highest GST activities were observed at 24 h. PT (2644 nmol/min.mg protein) and 48 101 
h. PT (2519 nmol/min.mg protein). Both enzymes resulted 3.5-3.7 fold higher compared to that 102 
measured in the cytosolic fraction from control flukes. The activity for both enzymes returned at 103 
60 h PT to basal levels similar to non-exposed flukes (Table 1A).The highest activities for CBR 104 
(16.82 nmol/min/mg protein), were observed at 48 h PT. This values resulted significative higher 105 
(5.6 fold higher) compared to that measured in the cytosolic fraction (3 nmol/min/mg protein) 106 
from control flukes. At 60 h PT the CBR activity (8.8 nmol/min/mg protein) resulted 2.9 fold 107 
higher than obtained in those measured in non-exposed flukes (Table 1A). 108 
TCBZ is metabolized into TCBZSO by the host liver but also by the parasites subcellular fractions 109 
[18] which exhibits significantly higher sulfoxidative activity as compared to nematode and cestode 110 
parasites [11]. The liver flukes showed efficient oxidative biotransformation of the anthelmintic 111 
TCBZ into its sulfoxide derivative (TCBZSO) form, which exerts most of the toxic potential to the 112 
parasite. In the present work, TCBZSO concentration determination in fluke tissues showed a 113 
concentration peak of 6.35 nmol/100 mg of fluke protein at 24 h PT which was consistent with 114 
previous reports [11]. TCBZ action may induce secondary oxidative stress in F. hepatica, which 115 
may explain the observed increment in activities of the analyzed enzymes as a defensive 116 
mechanism. In fact, the highest activities of the enzymes analyzed in this work were observed when 117 
the peak TCBZSO concentration was measured within the flukes recovered from treated sheep. 118 
These preliminary results may be useful to further understand the mechanisms underlying the drug 119 
metabolism/disposition and activity in target helminthes parasites. The enzymes analyzed are 120 
candidates to participate actively in the development of resistance at TCBZ in F. hepatica. 121 
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Table 1 1 
A) Enzymatic activities of Carboxylesterase (CE) Glutathione S-Transferase (GST) and 2 
Carbonyl Reductase (CBR) measured in cytosolic (GST, CBR) and microsomal 3 
(CE) fractions of parasite specimens recovered from sheep treated with the 4 
flukicidal compound.  5 
Statistical significance: ns (not significative), ** (P< 0,001) and *** (P<0,0001) 6 
post ANOVA Bonferroni test (n=5). 7 
B) Concentrations (µg/g. of protein) of triclabendazole (TCBZ) and its metabolites 8 
TCBZSO (TCBZ sulphoxide) and TCBZSO2 (TCBZ sulphone) measured in 9 
parasite specimens recovered from sheep treated with TCBZ.  10 
References: PT: post-treatment, nd: not detected, na: not applicable  11 
 12 
Time PT 
(h) 
A B 
Enzymatic activities 
(nmol/mg. protein/min) 
Concentrations of TCBZ  
and its metabolites 
(µg/g. of protein) 
CE GST CBR TCBZ TCBZSO TCBZSO2 
0 1450 719 3 na na na 
3 1640 ns 756 ns 3.3 ns nd 0.80 0.08 
24 2910** 2644*** 7.85** 0.14 6.35 13.9 
48 5170*** 2519*** 16.82*** nd 1.73 11.1 
60 1400 ns 769 ns 8.8** nd 0.71 8.09 
 13 
Table(s)
